The xF+ Liquid Biopsy Panel represents a cutting-edge approach in non-invasive cancer diagnostics, utilizing circulating tumor DNA (ctDNA) to provide a snapshot of tumor genomics from a simple blood sample. This innovative panel is designed to detect a comprehensive range of genomic alterations across various cancer types, offering valuable insights into tumor dynamics and aiding in the personalization of treatment strategies.
By enabling the monitoring of tumor evolution and treatment response over time, the xF+ Liquid Biopsy Panel supports oncology care by providing real-time genomic data that informs decision-making. This approach is particularly advantageous for patients where traditional biopsy is not feasible, ensuring continuity of care through less invasive means.
The panel's integration into the clinical workflow is streamlined, designed to complement traditional tissue biopsy results, or stand-alone as a primary diagnostic tool in selecting and adjusting therapeutic courses. Its high sensitivity and specificity make it a potent tool for tracking disease progression and therapeutic efficacy, reinforcing the shift towards more personalized cancer management.
